Massive hope for pancreatic cancer pill after trial saw tumours vanish
Recent clinical trials have generated significant optimism regarding a new oral medication for pancreatic cancer, with reports indicating that tumors have either shrunk or become undetectable in some patients. This advancement is being hailed as one of the most substantial developments in the treatment of pancreatic cancer in recent decades.
In initial trials involving the drug daraxonrasib, combined with chemotherapy, cancer was found to be undetectable on scans in approximately 8% of the 61 participants who had been diagnosed with advanced pancreatic cancer that had metastasized. Additionally, nearly 90% of the participants experienced halted tumor growth. While these results are promising, medical professionals caution that it is still unclear how long the disease can be managed with this treatment and emphasize that it should not be regarded as a definitive cure.
Dr. Sam Godfrey from Cancer Research UK described the findings as "incredibly exciting," labeling this development as "the biggest leap forward in decades" for individuals battling pancreatic cancer. He remarked, "What this new drug has done is it's found a way of drugging the undruggable," highlighting the long-awaited progress in the treatment of a disease known for its low survival rates.
Pancreatic cancer is particularly challenging to treat, recognized as having the lowest survival rate among common cancers in the UK. Traditional chemotherapy often manages to reduce tumor size temporarily, but the cancer frequently recurs, with most patients surviving only a few months post-diagnosis rather than years. The introduction of daraxonrasib offers hope that patients may gain additional time, even if a permanent solution remains elusive.
The trial monitored participants for an average of 18 months, during which some did not experience any recurrence of cancer. However, longer-term studies will be essential to determine whether any patients can achieve remission and the duration of such outcomes.
Among the trial's notable statistics are:
- 90% of patients had their tumors stop growing.
- Over 60% experienced shrinkage or complete disappearance of tumors.
- Approximately 8% of participants had tumors that were undetectable on CT scans.
Dr. Wungki Park, associated with Memorial Sloan Kettering Cancer Center in the United States and involved in the trial, expressed optimism about the findings thus far. He stated, "We are beginning to see not only a higher percentage of tumor response rates, but also deeper responses and a near doubling in the duration of disease control, which may eventually translate into longer survival."
Daraxonrasib is classified as a KRAS inhibitor, a treatment that has already received approval in the United States. This medication functions by targeting and deactivating specific mutations known as RAS, which are prevalent in many pancreatic cancers and contribute to tumor growth. Given that similar mutations can be found in various other cancers, including lung and ovarian cancers, there is potential for this drug to benefit a wider patient population.
Dr. Godfrey expressed hope that the early successes observed in pancreatic cancer could eventually extend to other malignancies. He emphasized the importance of conducting longer trials to gather more comprehensive results, noting, "Cancer can come back, and even if scans show there is no sign of it, you don't necessarily know you are cancer-free until more time has passed."
Professor Elena Garralda, who chairs the European cancer conference EORTC where these findings are being shared with fellow medical professionals, remarked on the significance of the results, stating, "These results are exciting because they show the combined treatment could potentially significantly improve patients' overall survival, as well as the time before tumors start to grow again."
In the UK, pancreatic cancer affects approximately 11,500 individuals annually, leading to around 10,200 deaths, according to statistics from Cancer Research UK.